Latest Derma Sciences (DSCI) Headlines Wound De
Post# of 17
Posted On: 03/13/2014 7:44:38 AM
Latest Derma Sciences (DSCI) Headlines
Wound Debridement Products - Global Strategic Business Report
M2 - Wed Mar 12, 3:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ffjwkx/wound_debridement) has announced the addition of the "Wound Debridement Products - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Wound Debridement Products in US$ Thousand. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2012 through 2020. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 35 companies including many key and niche players such as: - Advanced Medical Solutions Group plc - ArthroCare Corporation - Coloplast A/S - Derma Sciences, Inc. - Misonix, Inc. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Market Trends And Issues 3. Product Overview 4. Strategic Corporate Developments 5. Focus On Select Global Players 6. Global Market Perspective III. Competitive Landscape For more information visit http://www.researchandmarkets.com/research/ff...ebridement About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Derma Sciences to Hold Fourth Quarter Financial Results Conference Call on March 14th
Business Wire - Mon Mar 10, 6:30AM CDT
Derma Sciences, Inc. (the "Company") (Nasdaq
SCI), a tissue regeneration company focused on advanced wound care, announced today that it will hold a conference call on March 14, 2014 to discuss the financial results for the fourth quarter of 2013. In addition, management will provide a business update and a discussion on recent and upcoming milestones.
Derma Sciences to Present at the 26th Annual ROTH Conference
Business Wire - Tue Mar 04, 6:30AM CST
Derma Sciences, Inc. (Nasdaq SCI), a tissue regeneration company focused on advanced wound care, announced today that Edward J. Quilty, the Company's chairman and chief executive officer, will present a corporate overview and update at the 26th Annual ROTH Conference on March 11, 2014 at 3:30 p.m. Pacific time. The conference is being held at the Ritz Carlton, Laguna Niguel in Dana Point, Calif. from March 9 through March 12.
Can Derma Sciences (DSCI) Continue to Rise? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 31, 6:33AM CST
Can Derma Sciences (DSCI) Continue to Rise?
Derma Sciences (DSCI) Jumps: Stock Rises 6.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 30, 8:21AM CST
Derma Sciences Inc. (DSCI) was a big mover last session, as the company saw its shares rise by over 6% on the day.
Derma Sciences Closes $86 Million Underwritten Public Offering of Common Stock, Including Full Over-Allotment
Business Wire - Wed Jan 29, 9:17AM CST
Derma Sciences, Inc. (the "Company") (Nasdaq: DSCI), a tissue regeneration company focused on advanced wound care, today announced the closing of an underwritten public offering of 7,500,000 shares of common stock at a price to the public of $11.50 per share, which includes the exercise of the underwriters' option to purchase 978,261 shares of common stock to cover over-allotments. Piper Jaffray & Co. and Canaccord Genuity Inc. were joint bookrunning managers for the offering. Oppenheimer & Co. Inc. and Roth Capital Partners were financial advisors to the Company.
International Wound Dressings Market - Forecasts to 2018
M2 - Wed Jan 29, 3:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/wgbxbp/wound_dressings) has announced the addition of the "International Wound Dressings Market - Forecasts to 2018" report to their offering. "International Wound Dressings Market - Forecasts to 2018", inspects the different types of segments and sub-segments within the market such as the product types such as traditional wound care which includes sutures, gauze tapes and sponges, surgical cotton swabs and tissue sealants etc. The details also include emerging and advanced technologies such as films, foam dressings, collagen, alginates, hydrocolloids and hydrogels. The market analysis includes the analysis for the major geographical regions; North America, Europe, Asia-Pacific and Rest of the World (RoW). The study entails the emerging economies and regional opportunities that will present themselves in the coming years. In addition, the research also includes the other regional factors that will influence the growth or decline of the market in these regions. The analysis covers a forecast period of 2012 - 2018 which includes the several milestones covered in all the years. This represents several aspects such as the political, economical, environmental, legal factors such as growth of economy, reimbursement and medical policies in various regions. The report is prepared in such a way so as to cover the focus areas of multiple stake-holders such as market players and manufacturers of wound care products, hospitals, doctors, other medical professionals, research institutes, venture capitalists and share holders of public companies. The report is expected to act as a influencing tool to enable stake-holders to make calculated strategic decisions related to their marketing, expansion and penetration, business strategies adopted by them. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Wound Dressings Market Analysis Chapter 4 Traditional Wound Dressings Market Chapter 5 Advanced Wound Dressings Market Chapter 6 Geographical Analysis Chapter 7 Company Profiles Companies Mentioned: - 3M Healthcare - BSN Medical GMBH and Co - Bristol-Myers Squibb - CONVATEC HEALTHCARE - Coloplast - Derma Sciences - Hollister - Johnson & Johnson - Kinetic Concepts - Medline Industries - Paul Hartmann - Smith & Nephew - Systagenix Wound Management For more information visit http://www.researchandmarkets.com/research/wg..._dressings
Nasdaq stocks posting largest volume increases
AP - Fri Jan 24, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Derma Sciences Announces Pricing of Underwritten Public Offering of Common Stock
Business Wire - Fri Jan 24, 8:00AM CST
Derma Sciences, Inc. (the "Company") (Nasdaq: DSCI), a tissue regeneration company focused on advanced wound care, today announced the pricing of an underwritten public offering of 6,521,739 shares of common stock at a price to the public of $11.50 per share. The Company has granted the underwriters a 30-day option to purchase an additional 978,261 shares of common stock to cover over-allotments, if any. The offering is expected to close on or about January 29, 2014, subject to customary closing conditions.
Derma Sciences Announces Commencement of Public Offering of Common Stock
Business Wire - Thu Jan 23, 3:01PM CST
Derma Sciences, Inc. (Nasdaq SCI), a tissue regeneration company focused on advanced wound care, today announced that it intends to offer shares of its common stock in a public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
2013 Report on the European Wound Care Management Market - Outlook and Forecasts to 2018
M2 - Thu Jan 23, 8:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/x3flwl/europe_wound_care) has announced the addition of the "2013 Report on the European Wound Care Management Market - Outlook and Forecasts to 2018" report to their offering. "2013 Report on the European Wound Care Management Market - Outlook and Forecasts to 2018", provides key market data on the Europe Wound Care Management market - United Kingdom, Germany, France, Italy and Spain. The report provides value (USD million) data for all the market categories - Compression Therapy, Advanced Wound Management, Pressure Relief Devices, Wound Closure Devices, Traditional Wound Management, Ostomy Drainage Bags, Negative Pressure Wound Therapy (NPWT), Tissue Engineering, Wound Debridement Devices and Automated Suturing Devices. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts. Key players covered in this report include Coloplast A/S, Paul Hartmann AG, Smith & Nephew Plc, ConvaTec Inc., Covidien plc, Molnlycke Health Care AB, Kinetic Concepts, Inc., ArjoHuntleigh, medi GmbH & Co. KG, Hill-Rom Holdings, Inc., SIGVARIS, Inc., B. Braun Melsungen AG, Hollister Incorporated, Ethicon, Inc., Takeda Pharmaceuticals International GmbH, Baxter International Inc., Laboratoires Urgo S.A. Key Topics Covered: 1 Table of Contents 2 Introduction 3 Wound Care Management in Europe 4 Wound Care Management In Germany 5 Wound Care Management In France 6 Wound Care Management In United Kingdom 7 Wound Care Management In Italy 8 Wound Care Management In Spain 9 Overview of Key Companies in Europe Wound Care Management Market 10 Wound Care Management Market Pipeline Products 11 Financial Deals Landscape 12 Recent Developments 13 Appendix Companies Mentioned: - 3M Health Care - Advanced Medical Solutions Group - Baxter International - Bsn Medical - Coloplast - Convatec - Covidien - Derma Sciences - Igrobe Rodar - Invacare Corporation - Johnson & Johnson - Julius Zorn - Karomed Limited - Laboratoires Innothera - Laboratoires Urgo - Lohmann & Rauscher Gmbh & Co - Medela - Ossur - Paramount Bed - Paul Hartmann - Sidhil Limited - Smith & Nephew - Synergy Health - Systagenix Wound Management - Talley Group Limited - Thuasne For more information visit http://www.researchandmarkets.com/research/x3...wound_care
Derma Sciences Announces Record Revenues for the 2013 Fourth Quarter and Full Year, Introduces 2014 Revenue Guidance, Provides Update on DSC127 Phase 3 Clinical Trials
Business Wire - Thu Jan 16, 6:00AM CST
--DSC127 clinical trial sites to be initiated in South Africa
Derma Sciences Enters the Skin Substitute Market with Licensing Agreement for Innovative Amniotic Membrane Wound Care Products
Business Wire - Tue Jan 14, 8:17AM CST
Derma Sciences, Inc. (Nasdaq SCI), a medical device and pharmaceutical company focused on advanced wound care, announces it has licensed exclusive rights to two novel human placental-derived tissue products for all dermal indications in the advanced wound care and burn markets from BioD LLC, a privately held company based in Memphis, Tenn. These products will be branded as AmnioMatrix(R) and launched during the third quarter of 2014, expanding Derma Sciences' portfolio of advanced wound care (AWC) products into the $500 million skin substitute market. Terms of the license include an upfront cash payment, royalties on product sales and performance-based milestones to be paid in cash and Derma Sciences stock options.
Emerging Growth Equities, Ltd. Initiates Coverage of Derma Sciences, Inc. (DSCI) With A BUY Rating And $21.00 Price Target
PR Newswire - Thu Jan 02, 8:55AM CST
Emerging Growth Equities, Ltd. initiates coverage of Derma Sciences, Inc. (NASDAQ: DSCI) with a BUY rating and a $21.00 price target. Derma Sciences, Inc. is a specialty medical device / pharmaceutical company focused on wound care and has a fully integrated manufacturing, marketing and supply organization to support its core.
Surgical Incision Closures - Global Strategic Business Report
M2 - Fri Dec 20, 5:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/nxk5pj/surgical_incision#summary) has announced the addition of the "Surgical Incision Closures - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. This report analyzes the worldwide markets for Surgical Incision Closures in US$ Million by the following Product Segments: - Stapler Products (Internal Stapler, Skin Staplers, Surgical/Ligature Clips, & Vascular Clips) - Suture Products (Absorbable Sutures, & Non Absorbable) - Tape Closures - Tissue Sealants. The report profiles 55 companies including many key and niche players such as: - 3M Healthcare (US) - Advanced Medical Solutions Group Plc (UK) - Aesculap AG & Co. KG (Germany) - Baxter International Inc. (US) - Covidien Ltd. (US) - Autosuture (US) - Syneture (US) - USS Sports Medicine (US) - Derma Sciences Inc. (US) - Ethicon, Inc. (US) - Genzyme Biosurgery (US) - Smith & Nephew (UK) - Teleflex Medical (US) Key Topics Covered: 1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 2. INDUSTRY OVERVIEW 3. PRODUCT ANALYSIS 4. PRODUCT LAUNCHES/APPROVALS 5. RECENT INDUSTRY ACTIVITY 6. STRATEGIC CORPORATE DEVELOPMENTS IN THE RECENT PAST - A PERSPECTIVE BUILDER 7. FOCUS ON SELECT PLAYERS 8. GLOBAL MARKET PERSPECTIVE 9. THE UNITED STATES 10. CANADA 11. JAPAN 12. EUROPE 13. ASIA-PACIFIC 14. LATIN AMERICA 15. REST OF WORLD COMPETITIVE LANDSCAPE Region/Country Players - The United States 45 - Canada 3 - Japan 1 - Europe 16 - Germany 6 - The United Kingdom 6 - Spain 1 - Rest of Europe 3 For more information visit http://www.researchandmarkets.com/research/nx...on#summary
EMRISE Receives $1 Million Network Access Products Order
GlobeNewswire - Thu Dec 19, 7:45AM CST
EMRISE CORPORATION (OTCQB:EMRI), a multi-national manufacturer of defense and aerospace electronic devices and communications equipment, today announced that it has received an order for approximately $1 million in network access products for use in a high profile network application to be installed by a European government.
Diabetic Foot Ulcer Market in Rapid Race to Reach More than $1.5 Billion Value
M2 - Mon Dec 09, 2:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/vgwpgb/opportunityanalyze) has announced the addition of the "OpportunityAnalyzer: Diabetic Foot Ulcers - Opportunity Analysis and Forecast to 2017" report to their offering. The diabetic foot ulcer (DFU) treatment market will undergo impressive growth over a five-year period, increasing from $302m in 2012 to $1.58 billion by the end of 2017, at a substantial Compound Annual Growth Rate (CAGR) of 39.9%, according to a new report from research and consulting firm The authors. The company's latest report* states that out of the six major markets (6MM) - the US, France, Germany, Italy, Spain and the UK - the US contributed to the majority of the sales in 2012, generating an estimated $238m. It will continue to hold this status in 2017, when it will represent a massive 85% share of the global market with sales of around $1.34 billion. The authors anticipates a number of driving factors to propel the DFU market value to more than $1.5 billion over the next four years. Primarily, it will be given a leg up by the introduction of three novel wound-healing agents: Macrocure's CureXcell, Derma Sciences' DSC127 and Olympus Biotech's trafermin. These treatments are administrated either as a topical ointment or spray, or are injected directly into the wound bed. The imminent launch of the first two topical antibacterials indicated specifically for the treatment of diabetic foot infections will also lend a hand to the market growth. Innocoll's Cogenzia and Dipexium Pharmaceuticals' Locilex will be used either as an adjunct to systemic antibiotic therapy, or else to treat mild infections. Dr. Haylyn Wong, The authors's Analyst covering Cardiovascular and Metabolic Disorders, says: In addition to the anticipated arrival of these key products in the DFU marketplace, an increased emphasis will also be placed on the cost-effectiveness of advanced DFU treatments in preventing serious complications, such as infection, amputation and death. This will prove a particularly important driver behind the market, as the number of patients suffering from DFU is also expected to increase with the rising global prevalence of diabetes. According to The authors, the substantial growth in the DFU market will still be hindered by various limiting factors over the forecast period. These include what are expected to be high prices for the wound-healing agents currently in development, along with the fact that physician familiarity with widely-used systemic antibiotics may inhibit the uptake of novel topical antibacterials. However, Dr. Wong says: Although there are still a number of barriers in place, the DFU market is set to enter an exciting phase, kick-started by the launch of several much-anticipated, novel products into the treatment arena. This report provides an overview of DFUs, including epidemiology, etiology, pathophysiology, symptoms, diagnosis and treatment guidelines. It includes annualized DFU therapeutics market revenue, along with pipeline analysis and a review of the key industry drivers, restraints and challenges. Key Topics Covered: 1.1 List of Tables 1.2 List of Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Current Treatment Options 6 Unmet Needs Assessment and Opportunity Analysis 7 Research and Development Strategies 8 Pipeline Assessment 9 Pipeline Valuation Analysis 10 Appendix For more information visit http://www.researchandmarkets.com/research/vg...ityanalyze About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Derma Sciences to Present at the Oppenheimer & Co. Inc. 24th Annual Healthcare Conference
Business Wire - Wed Dec 04, 8:00AM CST
Derma Sciences, Inc. (Nasdaq SCI), a medical device and pharmaceutical company focused on advanced wound care, announced today that Barry Wolfenson, the Company's Group President, Advanced Wound Care and Pharmaceutical Development will present at the 24th Annual Oppenheimer & Co. Healthcare Conference at 9:10 a.m. ET on December 10th. The conference will be held at the Crowne Plaza Hotel in New York City from December 10th to 11th.
Wound Debridement Products - Global Strategic Business Report
M2 - Wed Mar 12, 3:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ffjwkx/wound_debridement) has announced the addition of the "Wound Debridement Products - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Wound Debridement Products in US$ Thousand. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2012 through 2020. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 35 companies including many key and niche players such as: - Advanced Medical Solutions Group plc - ArthroCare Corporation - Coloplast A/S - Derma Sciences, Inc. - Misonix, Inc. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Market Trends And Issues 3. Product Overview 4. Strategic Corporate Developments 5. Focus On Select Global Players 6. Global Market Perspective III. Competitive Landscape For more information visit http://www.researchandmarkets.com/research/ff...ebridement About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Derma Sciences to Hold Fourth Quarter Financial Results Conference Call on March 14th
Business Wire - Mon Mar 10, 6:30AM CDT
Derma Sciences, Inc. (the "Company") (Nasdaq
SCI), a tissue regeneration company focused on advanced wound care, announced today that it will hold a conference call on March 14, 2014 to discuss the financial results for the fourth quarter of 2013. In addition, management will provide a business update and a discussion on recent and upcoming milestones. Derma Sciences to Present at the 26th Annual ROTH Conference
Business Wire - Tue Mar 04, 6:30AM CST
Derma Sciences, Inc. (Nasdaq
SCI), a tissue regeneration company focused on advanced wound care, announced today that Edward J. Quilty, the Company's chairman and chief executive officer, will present a corporate overview and update at the 26th Annual ROTH Conference on March 11, 2014 at 3:30 p.m. Pacific time. The conference is being held at the Ritz Carlton, Laguna Niguel in Dana Point, Calif. from March 9 through March 12. Can Derma Sciences (DSCI) Continue to Rise? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 31, 6:33AM CST
Can Derma Sciences (DSCI) Continue to Rise?
Derma Sciences (DSCI) Jumps: Stock Rises 6.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 30, 8:21AM CST
Derma Sciences Inc. (DSCI) was a big mover last session, as the company saw its shares rise by over 6% on the day.
Derma Sciences Closes $86 Million Underwritten Public Offering of Common Stock, Including Full Over-Allotment
Business Wire - Wed Jan 29, 9:17AM CST
Derma Sciences, Inc. (the "Company") (Nasdaq: DSCI), a tissue regeneration company focused on advanced wound care, today announced the closing of an underwritten public offering of 7,500,000 shares of common stock at a price to the public of $11.50 per share, which includes the exercise of the underwriters' option to purchase 978,261 shares of common stock to cover over-allotments. Piper Jaffray & Co. and Canaccord Genuity Inc. were joint bookrunning managers for the offering. Oppenheimer & Co. Inc. and Roth Capital Partners were financial advisors to the Company.
International Wound Dressings Market - Forecasts to 2018
M2 - Wed Jan 29, 3:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/wgbxbp/wound_dressings) has announced the addition of the "International Wound Dressings Market - Forecasts to 2018" report to their offering. "International Wound Dressings Market - Forecasts to 2018", inspects the different types of segments and sub-segments within the market such as the product types such as traditional wound care which includes sutures, gauze tapes and sponges, surgical cotton swabs and tissue sealants etc. The details also include emerging and advanced technologies such as films, foam dressings, collagen, alginates, hydrocolloids and hydrogels. The market analysis includes the analysis for the major geographical regions; North America, Europe, Asia-Pacific and Rest of the World (RoW). The study entails the emerging economies and regional opportunities that will present themselves in the coming years. In addition, the research also includes the other regional factors that will influence the growth or decline of the market in these regions. The analysis covers a forecast period of 2012 - 2018 which includes the several milestones covered in all the years. This represents several aspects such as the political, economical, environmental, legal factors such as growth of economy, reimbursement and medical policies in various regions. The report is prepared in such a way so as to cover the focus areas of multiple stake-holders such as market players and manufacturers of wound care products, hospitals, doctors, other medical professionals, research institutes, venture capitalists and share holders of public companies. The report is expected to act as a influencing tool to enable stake-holders to make calculated strategic decisions related to their marketing, expansion and penetration, business strategies adopted by them. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Wound Dressings Market Analysis Chapter 4 Traditional Wound Dressings Market Chapter 5 Advanced Wound Dressings Market Chapter 6 Geographical Analysis Chapter 7 Company Profiles Companies Mentioned: - 3M Healthcare - BSN Medical GMBH and Co - Bristol-Myers Squibb - CONVATEC HEALTHCARE - Coloplast - Derma Sciences - Hollister - Johnson & Johnson - Kinetic Concepts - Medline Industries - Paul Hartmann - Smith & Nephew - Systagenix Wound Management For more information visit http://www.researchandmarkets.com/research/wg..._dressings
Nasdaq stocks posting largest volume increases
AP - Fri Jan 24, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Derma Sciences Announces Pricing of Underwritten Public Offering of Common Stock
Business Wire - Fri Jan 24, 8:00AM CST
Derma Sciences, Inc. (the "Company") (Nasdaq: DSCI), a tissue regeneration company focused on advanced wound care, today announced the pricing of an underwritten public offering of 6,521,739 shares of common stock at a price to the public of $11.50 per share. The Company has granted the underwriters a 30-day option to purchase an additional 978,261 shares of common stock to cover over-allotments, if any. The offering is expected to close on or about January 29, 2014, subject to customary closing conditions.
Derma Sciences Announces Commencement of Public Offering of Common Stock
Business Wire - Thu Jan 23, 3:01PM CST
Derma Sciences, Inc. (Nasdaq
SCI), a tissue regeneration company focused on advanced wound care, today announced that it intends to offer shares of its common stock in a public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. 2013 Report on the European Wound Care Management Market - Outlook and Forecasts to 2018
M2 - Thu Jan 23, 8:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/x3flwl/europe_wound_care) has announced the addition of the "2013 Report on the European Wound Care Management Market - Outlook and Forecasts to 2018" report to their offering. "2013 Report on the European Wound Care Management Market - Outlook and Forecasts to 2018", provides key market data on the Europe Wound Care Management market - United Kingdom, Germany, France, Italy and Spain. The report provides value (USD million) data for all the market categories - Compression Therapy, Advanced Wound Management, Pressure Relief Devices, Wound Closure Devices, Traditional Wound Management, Ostomy Drainage Bags, Negative Pressure Wound Therapy (NPWT), Tissue Engineering, Wound Debridement Devices and Automated Suturing Devices. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts. Key players covered in this report include Coloplast A/S, Paul Hartmann AG, Smith & Nephew Plc, ConvaTec Inc., Covidien plc, Molnlycke Health Care AB, Kinetic Concepts, Inc., ArjoHuntleigh, medi GmbH & Co. KG, Hill-Rom Holdings, Inc., SIGVARIS, Inc., B. Braun Melsungen AG, Hollister Incorporated, Ethicon, Inc., Takeda Pharmaceuticals International GmbH, Baxter International Inc., Laboratoires Urgo S.A. Key Topics Covered: 1 Table of Contents 2 Introduction 3 Wound Care Management in Europe 4 Wound Care Management In Germany 5 Wound Care Management In France 6 Wound Care Management In United Kingdom 7 Wound Care Management In Italy 8 Wound Care Management In Spain 9 Overview of Key Companies in Europe Wound Care Management Market 10 Wound Care Management Market Pipeline Products 11 Financial Deals Landscape 12 Recent Developments 13 Appendix Companies Mentioned: - 3M Health Care - Advanced Medical Solutions Group - Baxter International - Bsn Medical - Coloplast - Convatec - Covidien - Derma Sciences - Igrobe Rodar - Invacare Corporation - Johnson & Johnson - Julius Zorn - Karomed Limited - Laboratoires Innothera - Laboratoires Urgo - Lohmann & Rauscher Gmbh & Co - Medela - Ossur - Paramount Bed - Paul Hartmann - Sidhil Limited - Smith & Nephew - Synergy Health - Systagenix Wound Management - Talley Group Limited - Thuasne For more information visit http://www.researchandmarkets.com/research/x3...wound_care
Derma Sciences Announces Record Revenues for the 2013 Fourth Quarter and Full Year, Introduces 2014 Revenue Guidance, Provides Update on DSC127 Phase 3 Clinical Trials
Business Wire - Thu Jan 16, 6:00AM CST
--DSC127 clinical trial sites to be initiated in South Africa
Derma Sciences Enters the Skin Substitute Market with Licensing Agreement for Innovative Amniotic Membrane Wound Care Products
Business Wire - Tue Jan 14, 8:17AM CST
Derma Sciences, Inc. (Nasdaq
SCI), a medical device and pharmaceutical company focused on advanced wound care, announces it has licensed exclusive rights to two novel human placental-derived tissue products for all dermal indications in the advanced wound care and burn markets from BioD LLC, a privately held company based in Memphis, Tenn. These products will be branded as AmnioMatrix(R) and launched during the third quarter of 2014, expanding Derma Sciences' portfolio of advanced wound care (AWC) products into the $500 million skin substitute market. Terms of the license include an upfront cash payment, royalties on product sales and performance-based milestones to be paid in cash and Derma Sciences stock options. Emerging Growth Equities, Ltd. Initiates Coverage of Derma Sciences, Inc. (DSCI) With A BUY Rating And $21.00 Price Target
PR Newswire - Thu Jan 02, 8:55AM CST
Emerging Growth Equities, Ltd. initiates coverage of Derma Sciences, Inc. (NASDAQ: DSCI) with a BUY rating and a $21.00 price target. Derma Sciences, Inc. is a specialty medical device / pharmaceutical company focused on wound care and has a fully integrated manufacturing, marketing and supply organization to support its core.
Surgical Incision Closures - Global Strategic Business Report
M2 - Fri Dec 20, 5:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/nxk5pj/surgical_incision#summary) has announced the addition of the "Surgical Incision Closures - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. This report analyzes the worldwide markets for Surgical Incision Closures in US$ Million by the following Product Segments: - Stapler Products (Internal Stapler, Skin Staplers, Surgical/Ligature Clips, & Vascular Clips) - Suture Products (Absorbable Sutures, & Non Absorbable) - Tape Closures - Tissue Sealants. The report profiles 55 companies including many key and niche players such as: - 3M Healthcare (US) - Advanced Medical Solutions Group Plc (UK) - Aesculap AG & Co. KG (Germany) - Baxter International Inc. (US) - Covidien Ltd. (US) - Autosuture (US) - Syneture (US) - USS Sports Medicine (US) - Derma Sciences Inc. (US) - Ethicon, Inc. (US) - Genzyme Biosurgery (US) - Smith & Nephew (UK) - Teleflex Medical (US) Key Topics Covered: 1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 2. INDUSTRY OVERVIEW 3. PRODUCT ANALYSIS 4. PRODUCT LAUNCHES/APPROVALS 5. RECENT INDUSTRY ACTIVITY 6. STRATEGIC CORPORATE DEVELOPMENTS IN THE RECENT PAST - A PERSPECTIVE BUILDER 7. FOCUS ON SELECT PLAYERS 8. GLOBAL MARKET PERSPECTIVE 9. THE UNITED STATES 10. CANADA 11. JAPAN 12. EUROPE 13. ASIA-PACIFIC 14. LATIN AMERICA 15. REST OF WORLD COMPETITIVE LANDSCAPE Region/Country Players - The United States 45 - Canada 3 - Japan 1 - Europe 16 - Germany 6 - The United Kingdom 6 - Spain 1 - Rest of Europe 3 For more information visit http://www.researchandmarkets.com/research/nx...on#summary
EMRISE Receives $1 Million Network Access Products Order
GlobeNewswire - Thu Dec 19, 7:45AM CST
EMRISE CORPORATION (OTCQB:EMRI), a multi-national manufacturer of defense and aerospace electronic devices and communications equipment, today announced that it has received an order for approximately $1 million in network access products for use in a high profile network application to be installed by a European government.
Diabetic Foot Ulcer Market in Rapid Race to Reach More than $1.5 Billion Value
M2 - Mon Dec 09, 2:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/vgwpgb/opportunityanalyze) has announced the addition of the "OpportunityAnalyzer: Diabetic Foot Ulcers - Opportunity Analysis and Forecast to 2017" report to their offering. The diabetic foot ulcer (DFU) treatment market will undergo impressive growth over a five-year period, increasing from $302m in 2012 to $1.58 billion by the end of 2017, at a substantial Compound Annual Growth Rate (CAGR) of 39.9%, according to a new report from research and consulting firm The authors. The company's latest report* states that out of the six major markets (6MM) - the US, France, Germany, Italy, Spain and the UK - the US contributed to the majority of the sales in 2012, generating an estimated $238m. It will continue to hold this status in 2017, when it will represent a massive 85% share of the global market with sales of around $1.34 billion. The authors anticipates a number of driving factors to propel the DFU market value to more than $1.5 billion over the next four years. Primarily, it will be given a leg up by the introduction of three novel wound-healing agents: Macrocure's CureXcell, Derma Sciences' DSC127 and Olympus Biotech's trafermin. These treatments are administrated either as a topical ointment or spray, or are injected directly into the wound bed. The imminent launch of the first two topical antibacterials indicated specifically for the treatment of diabetic foot infections will also lend a hand to the market growth. Innocoll's Cogenzia and Dipexium Pharmaceuticals' Locilex will be used either as an adjunct to systemic antibiotic therapy, or else to treat mild infections. Dr. Haylyn Wong, The authors's Analyst covering Cardiovascular and Metabolic Disorders, says: In addition to the anticipated arrival of these key products in the DFU marketplace, an increased emphasis will also be placed on the cost-effectiveness of advanced DFU treatments in preventing serious complications, such as infection, amputation and death. This will prove a particularly important driver behind the market, as the number of patients suffering from DFU is also expected to increase with the rising global prevalence of diabetes. According to The authors, the substantial growth in the DFU market will still be hindered by various limiting factors over the forecast period. These include what are expected to be high prices for the wound-healing agents currently in development, along with the fact that physician familiarity with widely-used systemic antibiotics may inhibit the uptake of novel topical antibacterials. However, Dr. Wong says: Although there are still a number of barriers in place, the DFU market is set to enter an exciting phase, kick-started by the launch of several much-anticipated, novel products into the treatment arena. This report provides an overview of DFUs, including epidemiology, etiology, pathophysiology, symptoms, diagnosis and treatment guidelines. It includes annualized DFU therapeutics market revenue, along with pipeline analysis and a review of the key industry drivers, restraints and challenges. Key Topics Covered: 1.1 List of Tables 1.2 List of Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Current Treatment Options 6 Unmet Needs Assessment and Opportunity Analysis 7 Research and Development Strategies 8 Pipeline Assessment 9 Pipeline Valuation Analysis 10 Appendix For more information visit http://www.researchandmarkets.com/research/vg...ityanalyze About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Derma Sciences to Present at the Oppenheimer & Co. Inc. 24th Annual Healthcare Conference
Business Wire - Wed Dec 04, 8:00AM CST
Derma Sciences, Inc. (Nasdaq
SCI), a medical device and pharmaceutical company focused on advanced wound care, announced today that Barry Wolfenson, the Company's Group President, Advanced Wound Care and Pharmaceutical Development will present at the 24th Annual Oppenheimer & Co. Healthcare Conference at 9:10 a.m. ET on December 10th. The conference will be held at the Crowne Plaza Hotel in New York City from December 10th to 11th. 
(0)
(0)Derma Sciences (DSCI) Stock Research Links
Scroll down for more posts ▼